DE69617916D1 - Beta-a4 peptid spezifischer monoklonaler antikörper - Google Patents

Beta-a4 peptid spezifischer monoklonaler antikörper

Info

Publication number
DE69617916D1
DE69617916D1 DE69617916T DE69617916T DE69617916D1 DE 69617916 D1 DE69617916 D1 DE 69617916D1 DE 69617916 T DE69617916 T DE 69617916T DE 69617916 T DE69617916 T DE 69617916T DE 69617916 D1 DE69617916 D1 DE 69617916D1
Authority
DE
Germany
Prior art keywords
instant invention
monoclonal antibody
beta
specific monoclonal
peptide specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69617916T
Other languages
English (en)
Other versions
DE69617916T2 (de
Inventor
Gerhard Konig
Paul Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23534218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69617916(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of DE69617916D1 publication Critical patent/DE69617916D1/de
Publication of DE69617916T2 publication Critical patent/DE69617916T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69617916T 1995-02-14 1996-02-14 Beta-a4 peptid spezifischer monoklonaler antikörper Expired - Fee Related DE69617916T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/388,463 US5786180A (en) 1995-02-14 1995-02-14 Monoclonal antibody 369.2B specific for β A4 peptide
PCT/US1996/002491 WO1996025435A1 (en) 1995-02-14 1996-02-14 MONOCLONAL ANTIBODY SPECIFIC FOR βA4 PEPTIDE

Publications (2)

Publication Number Publication Date
DE69617916D1 true DE69617916D1 (de) 2002-01-24
DE69617916T2 DE69617916T2 (de) 2002-05-16

Family

ID=23534218

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69617916T Expired - Fee Related DE69617916T2 (de) 1995-02-14 1996-02-14 Beta-a4 peptid spezifischer monoklonaler antikörper
DE69637150T Expired - Lifetime DE69637150T3 (de) 1995-02-14 1996-02-14 Für das Beta-A4 (1-42) Peptid spezifischer monoklonaler Antikörper

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637150T Expired - Lifetime DE69637150T3 (de) 1995-02-14 1996-02-14 Für das Beta-A4 (1-42) Peptid spezifischer monoklonaler Antikörper

Country Status (11)

Country Link
US (3) US5786180A (de)
EP (3) EP0809656B1 (de)
JP (1) JP3115606B2 (de)
AT (2) ATE365750T1 (de)
CA (1) CA2212887C (de)
DE (2) DE69617916T2 (de)
DK (2) DK0809656T3 (de)
ES (3) ES2288896T5 (de)
HK (1) HK1114105A1 (de)
PT (2) PT809656E (de)
WO (1) WO1996025435A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
ES2136535B1 (es) * 1997-04-15 2000-08-16 Consejo Superior Investigacion Peptido sintetico para la produccion de anticuerpos contra el peptido beta amiloide 1-42.
KR20010006393A (ko) * 1997-04-16 2001-01-26 이곤 이 버그 β-아밀로이드 펩타이드-결합 단백질 및 이를 암호화하는 폴리뉴클레오타이드
US7005295B1 (en) 1997-04-16 2006-02-28 Wyeth β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
AU4007599A (en) 1998-05-21 1999-12-06 University Of Tennessee Research Corporation, The Methods for amyloid removal using anti-amyloid antibodies
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
AU2003262458B2 (en) * 1998-05-21 2008-06-19 University Of Tennessee Research Foundation Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1409654B1 (de) * 1999-06-16 2008-08-20 Boston Biomedical Research Institute Immunologische kontrolle des beta-amyloid gehaltes in vivo
AU4178601A (en) 2000-02-24 2001-09-03 Univ Washington Humanized antibodies that sequester abeta peptide
CA2404237C (en) * 2000-04-05 2010-01-26 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
JP2003516929A (ja) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド アミロイド形成性疾患の予防および治療
CA2414772C (en) * 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
WO2002088306A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
ES2391905T3 (es) 2001-08-17 2012-11-30 Washington University Método de ensayo para la enfermedad de alzheimer
CA2477621A1 (en) * 2002-03-01 2003-09-12 Applera Corporation Determination of compatibility of a set of chemical modifications with an amino-acid chain
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040107871A1 (en) * 2002-08-09 2004-06-10 Defeo Maureen A. Aluminum trihydrate containing slurries
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EA016357B1 (ru) * 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
WO2006046644A1 (ja) * 2004-10-28 2006-05-04 Sanko Junyaku Co., Ltd. アルツハイマー病の検定方法及び診断試薬
CA2587487A1 (en) * 2004-11-12 2006-05-18 Pfizer, Inc. Method of measuring amyloid-beta peptides
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP2388274A1 (de) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Verfahren zur Reinigung von Anti-A-Beta-Antikörpern
CN101291692A (zh) * 2005-10-21 2008-10-22 默克制药公司 抗addl单克隆抗体及其应用
EP1954718B1 (de) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a-globulomer-antikörper, antigen bindende gruppen davon, entsprechende hybridome, nukleinsäuren, vektoren, wirtszellen, verfahren zur herstellung dieser antikörper, zusammensetzungen, die diese antikörper enthalten, verwendungen dieser antikörper und verfahren zur verwendung dieser antikörper
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CA2632822C (en) * 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP2325209A3 (de) 2006-03-23 2011-08-03 BioArtic Neuroscience AB Verbesserte protofibril selektive Antikörper und deren Verwendung
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008011348A2 (en) * 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
FR2903999B1 (fr) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
US20100104577A1 (en) * 2006-10-10 2010-04-29 Golde Todd E Methods and materials related to anti-a (beta) antibodies
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR101160385B1 (ko) 2007-01-18 2012-07-10 일라이 릴리 앤드 캄파니 페길화된 Ａβ ＦＡＢ
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2009445A1 (de) * 2007-06-29 2008-12-31 Institut Pasteur Verwendung von Einzeldomänen-Camelid-Antikörpern zur Entdeckung einer oligomeren Form eines Amyloid-Betapeptids und deren Anwendungen
EP2182983B1 (de) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
WO2009048539A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
EP2603524A1 (de) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta-bindende proteine
US9687447B2 (en) 2010-10-26 2017-06-27 Ac Immune S.A. Method for preparing liposome-based constructs
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
JP2012102131A (ja) * 2012-01-05 2012-05-31 Elan Pharma Internatl Ltd アミロイド形成性疾患の予防および治療
CN103665113A (zh) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 人Aβ42抗原决定簇多肽、抗原、抗体、用途及试剂盒
MX370725B (es) * 2012-10-15 2019-12-20 Medimmune Ltd Anticuerpos contra el beta-amiloide.
JP2016103980A (ja) * 2013-03-08 2016-06-09 パナソニックヘルスケア株式会社 ハイブリドーマ及びモノクローナル抗体
SI3166970T1 (sl) 2014-07-10 2021-09-30 Bioarctic Ab Izboljšana A-beta protofibril vezavna protitelesa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
CA2079880A1 (en) * 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection and methods of use of protease nexin-2
EP0683234B2 (de) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung

Also Published As

Publication number Publication date
DK0809656T3 (da) 2002-03-18
EP1160256A3 (de) 2002-11-06
CA2212887A1 (en) 1996-08-22
US5693753A (en) 1997-12-02
DK1160256T4 (da) 2012-01-09
EP1160256B2 (de) 2011-11-09
DE69617916T2 (de) 2002-05-16
DK1160256T3 (da) 2007-10-22
EP1160256A2 (de) 2001-12-05
EP1842859A2 (de) 2007-10-10
ES2288896T5 (es) 2012-02-16
DE69637150T2 (de) 2008-02-28
WO1996025435A1 (en) 1996-08-22
DE69637150D1 (de) 2007-08-09
JPH10509736A (ja) 1998-09-22
EP1160256B8 (de) 2009-04-01
ES2167548T3 (es) 2002-05-16
DE69637150T3 (de) 2012-03-15
US5679531A (en) 1997-10-21
EP0809656A1 (de) 1997-12-03
EP1160256B1 (de) 2007-06-27
HK1114105A1 (en) 2008-10-24
ES2400674T3 (es) 2013-04-11
ATE210681T1 (de) 2001-12-15
MX9706189A (es) 1997-11-29
ES2288896T3 (es) 2008-02-01
PT809656E (pt) 2002-06-28
PT1160256E (pt) 2007-10-08
CA2212887C (en) 2006-10-10
US5786180A (en) 1998-07-28
JP3115606B2 (ja) 2000-12-11
EP1842859A3 (de) 2007-11-28
ATE365750T1 (de) 2007-07-15
EP0809656B1 (de) 2001-12-12
EP1842859B1 (de) 2013-01-09

Similar Documents

Publication Publication Date Title
DE69617916D1 (de) Beta-a4 peptid spezifischer monoklonaler antikörper
ATE177754T1 (de) Fragmente von prion proteinen.
AT500379B8 (de) Tau-proteine
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE69129302T2 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
DK0500659T3 (da) Monoklonale antistoffer.
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
DK0594576T3 (da) Immunoafprøvninger for og monoklonale antistoffer over for prothrombin-aktivering-peptider og deres nedbrydningsprodukter
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
DE69607034T2 (de) Pcna bindende substanz
EP0725081A4 (de) MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE59709495D1 (de) Antikörper und immunoassay zum Nachweis von MIA
BR9702101A (pt) Hibridoma e anticorpo monoclonal
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
ATE171545T1 (de) Verfahren zur bestimmung des lysingehaltes von samen
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee